Drugs Made In America Acquisition Corp. Rights (DMAAR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Drugs Made In America Acquisition Corp. Rights stock (DMAAR) is currently trading at $0.04. WallStSmart rates DMAAR as Sell.
- DMAAR PE ratio analysis and historical PE chart
- DMAAR PS ratio (Price-to-Sales) history and trend
- DMAAR intrinsic value — DCF, Graham Number, EPV models
- DMAAR stock price prediction 2025 2026 2027 2028 2029 2030
- DMAAR fair value vs current price
- DMAAR insider transactions and insider buying
- Is DMAAR undervalued or overvalued?
- Drugs Made In America Acquisition Corp. Rights financial analysis — revenue, earnings, cash flow
- DMAAR Piotroski F-Score and Altman Z-Score
- DMAAR analyst price target and Smart Rating
Drugs Made In America Acquisition Corp. Rights
📊 No data available
Try selecting a different time range
Smart Analysis
Drugs Made In America Acquisition Corp. Rights (DMAAR) · 2 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and institutional own.. Significant fundamental concerns warrant caution or avoidance.
Drugs Made In America Acquisition Corp. Rights (DMAAR) Key Strengths (0)
Drugs Made In America Acquisition Corp. Rights (DMAAR) Areas to Watch (2)
Very low institutional interest at 0.00%
Micro-cap company with very limited liquidity and high volatility
Drugs Made In America Acquisition Corp. Rights (DMAAR) Detailed Analysis Report
Overall Assessment
This company scores 4/100 in our Smart Analysis, earning a F grade. Out of 2 metrics analyzed, 0 register as strengths (avg 0/10) while 2 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Institutional Own., Market Cap.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Institutional Own. improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Institutional Own. and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DMAAR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 12:57:05 PM
About Drugs Made In America Acquisition Corp. Rights(DMAAR)
NASDAQ
USA
Drugs Made In America Acquisition Corp. (DMAAR) is a special purpose acquisition company (SPAC) focused on merging with innovative pharmaceutical enterprises in the United States to strengthen domestic drug manufacturing capabilities. In response to increasing healthcare demands and prevailing global supply chain challenges, DMAAR aims to drive cost-effective production solutions that enhance the pharmaceutical landscape. Led by an experienced management team, the company is well-positioned to capitalize on strategic growth opportunities in the sector while delivering sustainable value to its shareholders and revitalizing American healthcare manufacturing.